Search

for
Search:

Glossarydeuruxolitinib

medication inhibiting enzymes to treat autoimmune hair loss

Deuruxolitinib is a medication that inhibits Janus kinase (JAK) enzymes, which are involved in the inflammatory process. It is being studied for its potential to treat conditions like alopecia areata, an autoimmune disorder that causes hair loss, by reducing the immune system's attack on hair follicles.

Related Terms

Sort by

Research

30 / 121 results

research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)

63 citations , July 2024 in “Journal of the American Academy of Dermatology”

Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.

research FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata

3 citations , November 2024 in “Clinical Research”

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

research Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients

2 citations , October 2025 in “Frontiers in Medicine”

Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.

research 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials

2 citations , September 2024 in “Journal of the American Academy of Dermatology”

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

research 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial

2 citations , September 2023 in “Journal of the American Academy of Dermatology”

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

research Most men choose eyebrows versus scalp hair: Response to Mostaghimi et al., “Evaluation of eyebrow and eyelash regrowth and patient satisfaction in the phase 3 THRIVE-AA2 trial of deuruxolitinib in adult patients with alopecia areata”

1 citations , February 2025 in “Journal of the American Academy of Dermatology”

Most men prefer keeping their eyebrows over scalp hair.

research Deuruxolitinib for Alopecia Areata.

January 2026 in “PubMed”

Deuruxolitinib is approved to treat severe alopecia areata in adults.

research Supplementary file 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx

October 2025 in “Figshare”

Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.

research Table 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx

October 2025 in “Figshare”

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.

research 60058 Change in patient-reported hair satisfaction during deuruxolitinib treatment of severe alopecia areata: Pooled data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 trials

September 2025 in “Journal of the American Academy of Dermatology”

Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.

research 62339 Improvement in anxiety and depression in adult patients with severe alopecia areata treated with deuruxolitinib: Pooled data from the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials

September 2025 in “Journal of the American Academy of Dermatology”

Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.

research JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata

May 2023

research 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata

September 2023 in “Journal of the American Academy of Dermatology”

research 42752 Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata

September 2023 in “Journal of the American Academy of Dermatology”

Systematic Review of Newer Agents for the Management of Alopecia Areata in Adults: Janus Kinase Inhibitors, Biologics and Phosphodiesterase-4 Inhibitors

research Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors

12 citations , December 2022 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.

research Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis

10 citations , January 2023 in “Acta dermato-venereologica”

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

research Janus kinase inhibitors for alopecia areata

7 citations , August 2023 in “Journal of the American Academy of Dermatology”

JAK inhibitors offer new hope for treating severe alopecia areata.

research Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review

3 citations , May 2023 in “Clinical drug investigation”

JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.

The Relative Efficacy of Monotherapy With Janus Kinase Inhibitors, Dupilumab and Apremilast in Adults With Alopecia Areata: Network Meta-Analyses of Clinical Trials

research The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials

2 citations , July 2023 in “Journal of cosmetic dermatology”

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

Search

for
Search:

Related Terms

Research

research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)

research FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata

research Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients

research 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials

research 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial

research Most men choose eyebrows versus scalp hair: Response to Mostaghimi et al., “Evaluation of eyebrow and eyelash regrowth and patient satisfaction in the phase 3 THRIVE-AA2 trial of deuruxolitinib in adult patients with alopecia areata”

research Deuruxolitinib for Alopecia Areata.

research Supplementary file 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx

research Table 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx

research 60058 Change in patient-reported hair satisfaction during deuruxolitinib treatment of severe alopecia areata: Pooled data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 trials

research 62339 Improvement in anxiety and depression in adult patients with severe alopecia areata treated with deuruxolitinib: Pooled data from the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials

research JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata

research 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata

research 42752 Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata

research Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors

research Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis

research Janus kinase inhibitors for alopecia areata

research Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review

research The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials

research Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review

research Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib

research Novel drugs of United States Food and Drug Administration approved in 2024

research Medicaid coverage of Janus kinase inhibitors for alopecia areata treatment

research Exploring novel management options for alopecia areata

research MODERN BIOLOGICAL TREATMENT METHODS FOR ALOPECIA AREATA: A COMPREHENSIVE REVIEW

research Evidence Synthesis Gone Awry: The Perils of Aggregating Ineffective or Unsafe Doses in Alopecia Areata Reviews

research Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review

research SYSTEMATIC REVIEW OF ORAL JANUS KINASE INHIBITORS IN ALOPECIA AREATA: INSIGHTS FROM 2020 TO 2025 STUDIES

research Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review

research A Concise Review on Novel Drugs Applied in Treatment of Alopecia